Related Experiment Video
Updated: May 31, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Clinical results of boron neutron capture therapy (BNCT) for glioblastoma
T Kageji1, Y Mizobuchi, S Nagahiro
1Department of Neurosurgery, Kagawa National Children's Hospital, Kagawa, Japan. kageji@clin.med.tokushima-u.ac.jp
Abstract:
The purpose of this study was to evaluate the clinical outcome of BSH-based intra-operative BNCT (IO-BNCT) and BSH and BPA-based non-operative BNCT (NO-BNCT). We have treated 23 glioblastoma patients with BNCT without any additional chemotherapy since 1998. The median survival time (MST) of BNCT was 19.5 months, and 2-year, 3-year and 5-year survival rates were 26.1%, 17.4% and 5.8%, respectively. This clinical result of BNCT in patients with GBM is superior to that of single treatment of conventional radiotherapy compared with historical data of conventional treatment.
